News

Net profit of Glenmark Pharmaceuticals rose 930.34% to Rs 482.92 crore in the quarter ended June 2026 as against Rs 46.87 crore during the previous quarter ended June 2025. Sales rose 28.52% to Rs 3931.73 crore in the quarter ended June 2026 as against Rs 3059.33 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales3931.733059.33 29 OPM %20.4718.98 - PBDT816.56548.73 49 PBT643.39418.81 54 NP482.9246.87 930 Powered by Capital Market - Live News

Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS� (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS� is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark`s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa�2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. According to IQVIA� sales data for the 12-month period ending May 2026, the Zyprexa� IntraMuscular Injection market achieved annual sales of approximately $25.4 million.

Glenmark Specialty S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC). India will serve as the first country in Glenmark`s licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). Glenmark also plans to enroll patients in Australia and South Korea, subject to regulatory approvals. The study is aligned with Jiangsu Hengrui Pharmaceuticals Co.`s ongoing parent Phase 3 trial in China. Glenmark aims to generate clinically relevant data across broader and more diverse patient populations, supporting the development of Trastuzumab rezetecan across Glenmark`s licensed markets. The randomized, controlled, multi-centre, Phase 3 trial is designed to evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab rezetecan in patients with HER2-expressing platinum-resistant ovarian cancer, a difficult-to-treat disease where treatment options remain limited, and outcomes continue to be poor. Conducting the trial across multiple geographies is expected to support the generation of evidence from diverse patient groups and strengthen the clinical data package for the therapy across Glenmark`s licensed markets.